Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod

被引：0
|
作者：
Zhang, Peijin [1 ]
Hosein, Fareeda [1 ]
Yu, Kyungha [1 ]
Walker, Susan [1 ]
Syto, Mary [1 ]
Tirucherai, Giridhar [1 ]
Murthy, Bindu [1 ]
Tatosian, Daniel [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1532/314
引用
收藏
页码：976 / 976
页数：1
相关论文
共 50 条
  • [21] Effect of mild hepatic impairment on the pharmacokinetics of pelacarsen
    Yan, Jing-He
    Taylor, Amanda
    Clough, Timothy
    Burmeister-Getz, Elise
    Pazdirkova, Marketa
    Russo, Cesare
    CIRCULATION, 2024, 150
  • [22] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [23] The Effects of Mild or Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol
    Bui, Khanh
    She, Fahua
    Sostek, Mark
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1368 - 1374
  • [24] An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib
    Magee, Mindy He
    Shearn, Shawn
    Shaddinger, Bonnie
    Fang, Zixing
    Glaser, Ruchira
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 1014 - 1021
  • [25] Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin
    Goldberg, Michael R.
    Wong, Shekman L.
    Shaw, Jeng-Pyng
    Kitt, Michael M.
    Barriere, Steven L.
    PHARMACOTHERAPY, 2010, 30 (01): : 35 - 42
  • [26] The Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Tofacitinib, an Orally Active Janus Kinase Inhibitor
    Lawendy, Nervin
    Lamba, Manisha
    Chan, Gary
    Wang, Rong
    Alvey, Christine W.
    Krishnaswami, Sriram
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (06): : 421 - 427
  • [27] The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor
    Nenad Sarapa
    Margaret R. Britto
    Michelle B. Mainka
    Kourosh Parivar
    European Journal of Clinical Pharmacology, 2005, 61 : 247 - 256
  • [28] Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration
    Corey, AE
    Agnew, JR
    King, EC
    Parekh, NJ
    Powell, JH
    Thompson, GA
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (05) : 1279 - 1286
  • [29] The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor
    Sarapa, N
    Britto, MR
    Mainka, MB
    Parivar, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (04) : 247 - 256
  • [30] EFFECT OF MODERATE OR SEVERE HEPATIC IMPAIRMENT ON CLARITHROMYCIN PHARMACOKINETICS
    CHU, SY
    GRANNEMAN, GR
    PICHOTTA, PJ
    DECOURT, JP
    GIRAULT, J
    FOURTILLAN, JB
    JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (05): : 480 - 485
12345